We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week

Journal Scan / Research · March 22, 2021

Veliparib and Lapatinib in Patients With Metastatic, Triple-Negative Breast Cancer

Breast Cancer Research

 

Additional Info

Disclosure statements are available on the authors' profiles:

Breast Cancer Research
An Open-Label, Pilot Study of Veliparib and Lapatinib in Patients With Metastatic, Triple-Negative Breast Cancer
Breast Cancer Res 2021 Mar 04;23(1)30, EM Stringer-Reasor, JE May, E Olariu, V Caterinicchia, Y Li, D Chen, DL Della Manna, GB Rocque, C Vaklavas, CI Falkson, LM Nabell, EP Acosta, A Forero-Torres, ES Yang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading